A retrospective study assessing the real-world clinical outcomes among the patients with relapsed/refractory Diffuse Large B-cell Lymphoma treated with more than or equal 3 lines therapies
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Antineoplastics (Primary) ; Brentuximab vedotin (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary) ; Nivolumab (Primary) ; Obinutuzumab (Primary) ; Pembrolizumab (Primary) ; Polatuzumab vedotin (Primary) ; Venetoclax (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 04 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association